durvalumab   Click here for help

GtoPdb Ligand ID: 7985

Synonyms: anti-B7H1 monoclonal antibody | Imfinzi® | MEDI-4736 | MEDI4736
Approved drug Immunopharmacology Ligand
durvalumab is an approved drug (FDA (2017), EMA (2018))
Compound class: Antibody
Comment: Durvalumab is a monoclonal antibody directed against programmed death-1 ligand-1 (PD-L1, aka CD274), an important immunopharmacological drug discovery target in immuno-oncology.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. A patent search suggests that the development and use of durvalumab may be covered by patent WO2011066389 [2], although we cannot verify this by peptide sequence matches as no sequences from this patent are pulled in a protein BLAST with the light or heavy variable regions of durvalumab peptide sequences. An X-ray crystal structure of the PD-L1/durvalumab complex has been submitted to the RCSB PDB (accession 5X8M) [1].
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2017), EMA (2018))
International Nonproprietary Names Click here for help
INN number INN
10010 durvalumab
Synonyms Click here for help
anti-B7H1 monoclonal antibody | Imfinzi® | MEDI-4736 | MEDI4736
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 528
Other databases
GtoPdb PubChem SID 249565666
Search PubMed clinical trials durvalumab
Search PubMed titles durvalumab
Search PubMed titles/abstracts durvalumab
Wikipedia Durvalumab